

#5

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No:  
L01-06CIP

In Re Application Of: **McGrogan & Snable**

Serial No.	Filing Date	Examiner	Group Art Unit
09/494,088	January 28, 2000	Jennifer Lee	1643

Title:

**Dopaminergic Cells**

Address to:  
**Assistant Commissioner for Patents**  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:
  1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,whichever occurs first.

Also submitted herewith is:

- a certification as specified in 37 CFR 1.97(e);

**OR**

- the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
JAN 21 2000  
CIVIL PLEADING  
0062/0016

**BEST AVAILABLE COPY**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
L01-06CIP

In Re Application Of: McGrogan & Snable

Serial No.  
09/494,088

Filing Date  
January 28, 2000

Examiner  
Jennifer Lee

Group Art Unit  
1643

Title:

Dopaminergic Cells

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 500422 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

) on \_\_\_\_\_  
(Date)

*Signature*

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Signature of Person Mailing Correspondence*

*Typed or Printed Name of Person Mailing Correspondence*

\*This certificate may only be used if paying by deposit account.

*Barbara J. Luther*  
*Signature*

Dated: July 11, 2000

**BEST AVAILABLE COPY**

CC:

**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

AIIT VOLKEL NU.

L01-06

SERIAL NO.

09/494,088

**APPLICANT(S)**  
**McGrogan & Snable**

**FILING DATE**

1/28/2000

GROUP

1643

## **U.S. PATENT DOCUMENTS**

~~BEST AVAILABLE COPY~~

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

Zigova and Sanberg. *Science & Medicine*, September/October 1999, pp. 18-27. "Neural Stem Cells for Brain Repair."

EXAMINER

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

DOCKET NUMBER (Optional)

L01-06CF

APPLICATION NUMBER

09/494,088

Applicant(s)

McGrogan &amp; Snable

Filing Date

January 28, 2000

Group Art Unit

1643

\*EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Sentman et al., Cell vol. 67(5):879-88, Nov. 29, 1991. "bcl-2 Inhibits Multiple Forms of Apoptosis..." (Medline abstract)

Lindvall. Nature Biotechnology Vol. 17:635-636, July 1999. "Engineering Neurons for Parkinson's Disease."

Wagner et al. Nature Biotechnology Vol. 17:653-659, July 1999. "Induction of a Midbrain Dopaminergic Phenotype in Nurr1-overexpressing Neural Stem Cells by Type 1 Astrocytes."

Mendez et al. J. Neurosci. Vol. 16(22):7216-7227, November 15, 1996. "Reconstruction of the Nigrostriatal Pathway by Simultaneous intrastriatal and Intranigral dopaminergic Transplants."

Adams et al. Biochem. Res. Vol. 21 (5):619-627, 1996. "Characterization and Transplantation of Two Neuronal Cell Lines with Dopaminergic Properties."

Pekosz et al. J. Virology. Vol. 70(8):5329-5335, Aug. 1996. "Induction of Apoptosis by La Crosse Virus Infection and Role of Neuronal Differentiation and Human bcl-2 Expression in Its Prevention."

Langeveld et al. Neurosci. Lett. Vol. 192:13-16, 1995. "Cultured Rat Striatal and Cortical Astrocytes Protect Mesencephalic Dopaminergic Neurons Against Hydrogen Peroxide Toxicity Independent of Their Effect on Neuronal Development."

Sanberg et al. Nature Medicine Vol. 3(10):1129-32, Oct. 1997. "Testis-Derived Sertoli Cells have a Trophic Effect on Dopamine Neurons and Alleviate Hemiparkinsonism in Rats."

**BEST AVAILABLE COPY**

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.